

Refine Search

Search Results -

Term	Documents
8.CLM. PGPB,USPT.	0
(L8.CLM.).PGPB,USPT.	0

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L9

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, October 25, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>		
<u>L9</u>	L8.clm.	0	<u>L9</u>
<u>L8</u>	(transforming growth factor\$)same(antibod\$ or immunoglobulin\$) same (diabetes or nephritis or glomerulonephritis)	86	<u>L8</u>
<u>L7</u>	L6.clm.	0	<u>L7</u>
<u>L6</u>	(tgf\$)same(antibod\$ or immunoglobulin\$) same (diabetes or nephritis or glomerulonephritis)	204	<u>L6</u>
<u>L5</u>	(L1 or L2) and (tgf\$)same(antibod\$ or immunoglobulin\$) same (diabetes or nephritis or glomerulonephritis).clm.	0	<u>L5</u>
<u>L4</u>	(L1 or L2) and (tgf\$)same(antibod\$ or immunoglobulin\$) same (diabetes or nephritis or glomerulonephritis)	7	<u>L4</u>
<u>L3</u>	(L1 or L2) and (tgf\$)same(antibod\$ or immunoglobulin\$) and (diabetes or nephritis or glomerulonephritis)	14	<u>L3</u>

L2 ruoslahti.in.

102 L2

L1 border.in.

335 L1

END OF SEARCH HISTORY

Search Results - Record(s) 1 through 10 of 14 returned.

- ☐ 1. [20050124534](#). 27 Sep 04. 09 Jun 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble, Nancy A., et al. 514/8; 424/145.1 424/94.64 514/381 514/423 514/44 A61K048/00 A61K038/48 A61K039/395 A61K031/4178 A61K031/401.
- ☐ 2. [20050037007](#). 08 Jul 04. 17 Feb 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble, Nancy A., et al. 424/145.1; 514/12 514/171 514/423 A61K039/395 A61K038/17 A61K031/56 A61K031/401.
- ☐ 3. [20040028682](#). 07 Aug 03. 12 Feb 04. Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix. [Border](#), Wayne A., et al. 424/145.1; 514/18 A61K039/395.
- ☐ 4. [20030032591](#). 21 Aug 01. 13 Feb 03. Inhibitors of cell regulatory factors and methods for preventing or reducing scarring. [Ruoslahti](#), Erkki I., et al. 514/12; 514/54 A61K038/17 A61K031/728.
- ☐ 5. [6906026](#). 05 Jul 01; 14 Jun 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble; Nancy A., et al. 514/2; 435/4 435/6 435/7.1 514/4 514/44. A61K048/00 A61K039/395 A61K038/00 .
- ☐ 6. [6509314](#). 13 Jun 94; 21 Jan 03. Methods of preventing or reducing scarring with decorin or biglycan. [Ruoslahti](#), Erkki I., et al. 514/8; 514/2 530/350. A01N061/00 A61K038/17 .
- ☐ 7. [6436900](#). 02 Jun 95; 20 Aug 02. Methods of treating a pathology or a fibrotic condition by administering decorin. [Ruoslahti](#), Erkki I., et al. 514/8; 514/12 514/2 530/350. A61K038/16 A61K038/02 A61K038/39 C07K014/435 .
- ☐ 8. [6316258](#). 15 Dec 98; 13 Nov 01. Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF. beta. using renin inhibitors. Noble; Nancy A., et al. 435/375; 435/7.1. G01N033/50 .
- ☐ 9. [6277812](#). 02 Jun 95; 21 Aug 01. Methods for inhibiting TGF-.beta. activity. [Ruoslahti](#), Erkki I., et al. 514/2; 435/69.1 514/8 530/395. A01N061/00 .
- ☐ 10. [5824655](#). 15 Feb 95; 20 Oct 98. Anti-transforming growth factor-.beta. gene therapy. [Border](#), Wayne A.. 514/44; 424/93.21 424/93.7 435/320.1 435/352 435/353 435/354 435/366 514/2. A01N043/04 .

Term	Documents
DIABETES	59800
DIABETE	252
NEPHRITIS	7194
NEPHRITI	2
GLOMERULONEPHRITIS	11112

Search Results - Record(s) 11 through 14 of 14 returned.

-
- ☐ 11. 5705609. 16 May 95; 06 Jan 98. Decorin fragments inhibiting cell regulatory factors. Ruoslahti; Erkki I., et al. 530/329; 530/324 530/399 930/10. C07K007/06 C07K014/435 A61K038/08 A61K038/17 .
-
- ☐ 12. 5654270. 08 Sep 94; 05 Aug 97. Use of fibromodulin to prevent or reduce dermal scarring. Ruoslahti; Erkki I., et al. 514/8; 435/69.1 514/2. C07K014/435 A61K038/17 .
-
- ☐ 13. 5583103. 14 Mar 94; 10 Dec 96. Inhibition of transforming growth factor beta activity. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350 530/380 530/399. A61K038/19 C07K014/495 .
-
- ☐ 14. 5453492. 28 Jul 93; 26 Sep 95. 60 kDa transforming growth factor-.beta.-binding protein and its use to detect or purify TGF-.beta.. Butzow; Ralf, et al.